ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0426

The Clinical Efficacy of Switching Therapy Between Biological Agents and JAK Inhibitors in the Patients with Rheumatoid Arthritis
Abstract Number: 0100

The Clinical Relevance of Different Antiphospholipid Antibody Profiles in Pediatric Rheumatology Patients
Abstract Number: 1116

The Current State of Sodium-Glucose Cotransporter Type 2 Inhibitor Use Among Patients with Gout at a Tertiary Academic Healthcare System
Abstract Number: 1342

The Delivery of the Super-repressor IκBα by Exosomes Has the Potential to Alleviate Inflammation Associated with Rheumatoid Arthritis
Abstract Number: 1033

The Detection of Subclinical Joint Inflammation by Thermal and Ultrasound Imaging at the Metacarpophalangeal Joints in Patients with Rheumatoid Arthritis
Abstract Number: 0793

The Dual Specificity Phosphatase 6 (DUSP6) Regulates Arthritis Severity and IL10 Production
Abstract Number: 1768

The Dynamics of the Gut Microbiome in Rheumatoid Arthritis Susceptibility: A Cross-Sectional and Longitudinal Observational Study
Abstract Number: 1494

The Effect of Belimumab on Steroid Use in Patients with SLE: Results from a Retrospective Observational Study of Real-World Data from a US Rheumatology Provider Network
Abstract Number: 2504

The Effect of Inflammatory Conditions on the Regulation of Canonical and Non-canonical NF-kB Pathways via Bcl11b
Abstract Number: 0778

The Effect of Probiotic Modulation of Enteral Dysbiosis on Disease Activity in Patients with Psoriatic Arthritis – A Randomized Controlled Trial
Abstract Number: 1736

The Effect of Resolvin E1 and Resolvin D1 Specialised Pro-resolving Mediators on the Inhibition of Osteoclastogenesis
Abstract Number: 2516

The Effect of Starting Prednisone Dose on the Treatment of Polymyalgia Rheumatica
Abstract Number: 1777

The Effect of the Inflamed Joint Microenvironment on Endothelial Cell Function
Abstract Number: 2564

The Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine in Patients with Systemic Autoimmune Rheumatic Diseases Using Immunomodulators: An Emulated Target Trial
Abstract Number: 0622

The Effectiveness of Breath-holding Test to Predict Pulmonary Function in Systemic Sclerosis Patients Using Machine Learning Model

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].